Year: 2024
Type: article
Abstract: According to the new WHO classification of 2021, gliomas are a heterogeneous group of tumors with very different histology, molecular genetics, and prognoses. In addition to glioblastomas, the most common gliomas, there are also numerous less common gliomas, some of which have a very favorable prognosis. Targeted radionuclide therapy is a therapeutic option that can be attractive if a tumor can be targeted based on its molecular characteristics. It is particularly useful when tumors cannot be completely resected or when conventional imaging does not fully capture the extent of the tumor. Numerous approaches to radionuclide therapy for gliomas are in early development. The most advanced approaches for patients with gliomas in the clinic employ L-type amino acid transporter 1 as an uptake mechanism for radiolabeled amino acids or target somatostatin receptor 2 or gastrin-releasing peptide receptor. Here, we discuss the various target structures of radionuclide therapy in gliomas and provide an outlook for which glioma entities radionuclide therapy could most likely provide a therapeutic alternative.
Source: Neuro-Oncology
Institutions: University of Zurich, University Hospital Zurich, LMU Klinikum, Ludwig-Maximilians-Universität München, Forschungszentrum Jülich, University of Cologne, University Hospital Cologne, Medical University of Vienna, New York University, Harvard University, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Deutsches Konsortium für Translationale Krebsforschung
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4401385510